Download PDF DATE: 10 July 2025 CATEGORY: PRESS RELEASE Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie Glenmark to develop, manufacture and…
Download PDF DATE: 10 July 2025 CATEGORY: PRESS RELEASE Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody ISB 2001 is…
Download PDF DATE: 02 June 2025 CATEGORY: PRESS RELEASE Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 ×…
Download PDF DATE: 05 May 2025 CATEGORY: PRESS RELEASE Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma Results from the dose-escalation…
DATE: 07 April 2024 CATEGORY: PRESS RELEASE Ichnos Glenmark Innovation Presents Preclinical Data for its Oncology Asset ISB 2001 at AACR 2024 Annual Meeting - ISB 2001 is a first-in-class…
DATE: 08 March 2024 CATEGORY: PRESS RELEASE Ichnos Glenmark Innovation reports the publication in Nature Communications of the preclinical development of ISB 1442 bispecific antibody for Treatment of Relapsed/Refractory Multiple…
DATE: 30 Jan 2024 CATEGORY: PRESS RELEASE Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - ‘Ichnos Glenmark Innovation’ FOR IMMEDIATE RELEASE…
DATE: 12 Dec 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Delivers Strong Evidence for its Trio of Oncology Assets at ASH 2023 Annual Meeting chnos presentations include clinical data on ISB…
